Home Quality Improvement Triglycerides QI Programme Module 3: TG QI Programme Module 3: Guidelines & treatment options This programme has been funded by Amarin Corp plc. Amarin were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by the PCCS. The information provided in this presentation is for educational purposes only. Prescribing or management decisions made by clinicians are exclusively their own responsibility. The speaker/PCCS bear no responsibility regarding management or prescribing decisions made by others, or otherwise. Downloadable slides Please download them here Resources and useful links TA805 - Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides NG238 - Cardiovascular disease: risk assessment and reduction, including lipid modification NHS Scotland - SMC2602 NHS AAC - Summary of national guidance for lipid management Northern England Evaluation and Lipid Intensification guideline HIN - Lipid management pathways Back to Module 2 Module 4 Quality Improvement Programme Triglycerides QI ProgrammeModule 1Module 2Module 3Module 4COVID-19 & CVD QI Programme IntroductionModule 1Module 2Module 3CKD QI Programme IntroductionModule 1Module 2Module 3Module 4Lipid QI ProgrammeModule 1 Module 2Module 3 Module 4 Additional ResourcesHeart Failure QI Programme Explore PCCS Member Benefits